DRIO · DarioHealth Corp. · Insider Trading

The reported shares were acquired pursuant to a Securities Purchase Agreement with the issuer, dated July 22, 2026, at a purchase price of $6.93 per share.

The restricted share award shall vest in two equal installments on the last day of each successive annual anniversary after the grant date over a two-year period.

The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025.

The restricted share award shall vest on the last day of the second-year anniversary after the grant date.

The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025.

The restricted share award shall vest in two equal installments on the last day of each successive annual anniversary after the grant date over a two-year period.

The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025.

The restricted share award shall vest on the last day of the second-year anniversary after the grant date.

The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025.

The restricted share award shall vest on the last day of the second-year anniversary after the grant date.

The restricted share award shall vest in two equal installments on the last day of each successive annual anniversary after the grant date over a two-year period.

The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025.

The restricted share award shall vest in two equal installments on the last day of each successive annual anniversary after the grant date over a two-year period.

The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025.

The restricted share award shall vest on the last day of the second-year anniversary after the grant date.

The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025.

The restricted share award shall vest on the last day of the second-year anniversary after the grant date.

The number of shares beneficially owned reflects the 20-for-1 reverse stock split effected on August 28, 2025.

The restricted shares vest over three years, with one third of such shares vesting on April 27, 2026, and the remaining shares vesting in equal quarterly amounts, subject to the Reporting Person's continued services to the Issuer on the applicable vesting date The vesting period shall immediately end, and all shares shall immediately vest, in the event of a change in control of the Registrant (as defined in the Registrant's 2020 Equity incentive Plan, as amended).

The Series D-2 Preferred Stock will automatically convert into shares of common stock, subject to shareholder approval and certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 12-month anniversary of the issuance date. The Series D-2 Preferred Stock initially converts into shares of common stock at a conversion price of $0.83. In addition, the holders of Series D-2 Preferred Stock will also be entitled dividends payable as follows: ten percent (10%) of the number of shares of Common Stock issuable upon conversion of the Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the Closing Date, all issuable upon conversion of the Preferred Stock.

Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date.

The Reporting Person's 50 shares of Series B-2 Preferred Stock automatically converted into 19,289 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 965 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 28,596 shares of Common Stock immediately following the conversion.

The options vest immediately upon achieving certain milestones relating to the achievement of revenues (on a U.S. generally accepted account principles basis) for the year ending December 31, 2024.

The options vest as follows: 400,000 shares begin to vest over three years in 12 equal quarterly amounts upon achieving certain milestones relating to the achievement of revenues (on a U.S. generally accepted account principles basis) for each of the years ending December 31, 2025, December 31, 2026 and December 31, 2027.

The options vest as follows: 500,00 shares vest over three years in three equal yearly amounts, subject to the Reporting Person's continued services to the Issuer on the applicable vesting date.

The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in quarterly instalments on the last day of each calendar quarter commencing March 31, 2024 for a two year period.

The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in quarterly instalments on the last day of each calendar quarter commencing March 31, 2024 for a two year period.

The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in two instalments on the last day of each successive annual anniversary over a two year period.

The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in two instalments on the last day of each successive annual anniversary over a two year period.

The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in quarterly instalments on the last day of each calendar quarter commencing March 31, 2024 for a two year period.

The option will vest upon reaching certain performance milestones between December 31, 2024 and March 31, 2025.

The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in two instalments on the last day of each successive annual anniversary over a two year period.

The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in quarterly instalments on the last day of each calendar quarter commencing March 31, 2024 for a two year period.

The shares vest as follows: (i) 50% vest on the grant date and (ii) 50% vest in two instalments on the last day of each successive annual anniversary over a two year period.

The options will vest over a two-year period commencing on the grant date, with 50% vesting on the grant date and 50% vesting in eight equal quarterly installments following the grant date, subject to the employee's continued employment by the Company.

The options vest immediately upon achieving certain milestones relating to the achievement of revenues (on a U.S. generally accepted account principals basis) for the year ending December 31, 2024, the achievement of certain operating expense targets for the years ending December 31, 2024 and December 31, 2025, the ability to generate software value from funds invested and meet product roadmap and the retention of key employees post transaction, subject in each case to the Reporting Person's continued services to the Issuer on the applicable vesting date.

The options vest as follows: 291,742 shares vest immediately, and the remaining 426,205 shares vest over two years in eight equal quarterly amounts, subject to subject to the Reporting Person's continued services to the Issuer on the applicable vesting date.

Subject to beneficial ownership limitations provided for in the offering documents relating to the sale of the Series-C Preferred Stock, each share of Series-C Preferred Stock shall automatically convert into shares of the registrant's common stock at the conversion price of $2.02 upon the earlier of (i) the 15-month anniversary of the effective date of the certificate of designation, or (ii) the consent to conversion by holders of at least 50.1% of the outstanding shares of Series-C Preferred.

The Series C Preferred Stock initially converts into shares of common stock at a conversion price of $2.02. In addition, the holders of Series c Preferred Stock will also be entitled dividends payable as follows: (i) a number of shares of Common Stock equal to seven and a half percent (7.5%) of the number of shares of Common Stock issuable upon conversion of the Series C Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the closing date, and (ii) a number of shares of common stock equal to fifteen percent (15%) of the number of shares of common stock issuable upon conversion of the Series C Preferred Stock then held by such holder on the fifth full quarter from the closing date.

The Series B Preferred Stock will automatically convert into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date.

The Series B Preferred Stock initially converts into shares of common stock at a conversion price of $3.37. In addition, the holders of Series B Preferred Stock will also be entitled dividends payable as follows: (i) a number of shares of Common Stock equal to five percent (5.0%) of the number of shares of Common Stock issuable upon conversion of the Series B Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the closing date, and (ii) a number of shares of common stock equal to ten percent (10%) of the number of shares of common stock issuable upon conversion of the Series B Preferred Stock then held by such holder on the fifth full quarter from the closing date.